Gene Therapy Induces Antigen-Specific Tolerance in Experimental Collagen-Induced Arthritis

Sara Tengvall1*, Tove Eneljung1,6*, Pernilla Jirholt1, Olof Turesson1, Kajsa Wing2, Rikard Holmdahl2,3, Jan Kihlberg4, Anna Stern1, Inga-Lill Mårtensson1, Louise Henningsson1, Kenth Gustafsson5, Inger Gjertsson1,6*

1 Department of Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, 2 Medical Inflammation Research, Dept of medical Biochemistry and biophysics, Karolinska Institutet, Stockholm, Sweden, 3 Southern Medical University, Guangzhou, PR China, 4 Department of Chemistry, BMC, Uppsala University, Uppsala, Sweden, 5 Molecular and Cellular Immunology Section, UCL Institute of Child Health, London, United Kingdom, 6 Sahlgrenska University Hospital, Gothenburg, Sweden

☯ These authors contributed equally to this work.
* inger.gjertsson@rheuma.gu.se

Abstract

Here, we investigate induction of immunological tolerance by lentiviral based gene therapy in a mouse model of rheumatoid arthritis, collagen II-induced arthritis (CIA). Targeting the expression of the collagen type II (CII) to antigen presenting cells (APCs) induced antigen-specific tolerance, where only 5% of the mice developed arthritis as compared with 95% of the control mice. In the CII-tolerized mice, the proportion of Tregs as well as mRNA expression of SOCS1 (suppressors of cytokine signaling 1) increased at day 3 after CII immunization. Transfer of B cells or non-B cell APC, as well as T cells, from tolerized to naïve mice all mediated a certain degree of tolerance. Thus, sustainable tolerance is established very early during the course of arthritis and is mediated by both B and non-B cells as APCs. This novel approach for inducing tolerance to disease specific antigens can be used for studying tolerance mechanisms, not only in CIA but also in other autoimmune diseases.

Introduction

The main feature of rheumatoid arthritis (RA) is loss of tolerance to self-antigens followed by inflammation and joint destruction. Immunosuppressive drugs reduce the immune response to self-antigens but unfortunately they also increase the risk for infections [1]. An ideal way to treat RA would be to re-establish tolerance without a general suppression of the immune system. However, therapeutic tolerance has not yet been achieved in clinical trials [2], largely because the tolerogenic mechanisms are poorly understood.

The most commonly used mouse model for RA is collagen type II (CII)-induced arthritis (CIA). CII-specific tolerance in CIA depends on presentation of an already identified CII-peptide (amino acids (aa) 259–270) [3] in complex with the major histocompatibility complex type II (MHCII) Aq molecule [4,5]. To study tolerance mechanisms, the CII protein or CII-
peptides in their native or modified forms have been administered via various routes and at different time points before induction or during the course of CIA: e.g. orally [6–8] intravenously [9], intraperitoneally [10] or nasally [11,12]. It has become apparent that the glycosylation pattern of CII is of major importance for tolerance induction in CIA [13,14], and that also truncated forms of the CII-peptide [15] can induce tolerance in mice provided that they still bind to the Aq molecule. These and other studies have provided invaluable data, but they have also highlighted at least two complications in tolerance induction. First, the tolerogen can also trigger a pathogenic immune activation under circumstances when the tolerogen has adjuvant properties, a risk that is increased if proteins are administered exogenously [16]. Second, the half life of the tolerogen is too short to be effective, e.g. when administered as peptides [17], and thereby only presented to the immune system at delivery time points. However, the mechanisms maintaining tolerance vary during the course of CIA and thus, even if tolerization time points prior CII-immunization are fine-tuned, a system that targets antigen presenting cells (APCs) and allows continuous expression of a tolerogenic CII-epitope is lacking.

Tolerance is not due to lack of immune stimulation but rather an active immune regulation that involves several different cell types. Adoptive transfer of CII-pulsed dendritic cells (DCs) [18,19] or indoleamine 2,3-dioxygenase (IDO) expressing [20,21] DCs from either orally CII tolerized mice or in vitro manipulated DCs have been found to alleviate, but not abrogate arthritis development. The effect seemed mainly to be attributed to induced Foxp3+ regulatory T cells (Tregs). Further supporting a role for Tregs in tolerance to CIA, another study showed a significant increase in the number of Tregs in CII tolerized mice [22]. B cells and CII-specific autoantibodies are hallmarks in CIA, and in the great majority of tolerance studies CII-specific antibodies decrease. However, not only the CII-specific antibodies, but also the B cells themselves are important in CIA, as B cell depletion delays the onset of arthritis [23]. B cells also seem to take an active part in tolerance induction since presentation of self-antigen by B cells results in Treg induction rather than in anergy or clonal deletion [24]. Also B regulatory cells are of importance for regulation of the joint specific immune response and development of CIA [25–28].

The suppressors of cytokine signaling (SOCS) protein family, which are induced by various cytokines, e.g. IL-10 [29] are important regulators of immune responses. The SOCS proteins exert their functions through negative feedback on the JAK/STAT pathway [30,31]. SOCS have been strongly implicated in regulation of autoimmune conditions, e.g. enhanced SOCS1 expression in NZB/W mice correlated with reduced IFN-γ production and restored the IFN-γ signaling pathway [32]. Further, up-regulation of SOCS1 and/or 3 in CIA coincided with increased IL-10 production and reduced severity of arthritis [33,34]. These effects are partly due to the importance of SOCS proteins in sustaining the regulatory phenotype of FoxP3+ cells and to create a tolerogenic cytokine milieu that prevents autoimmune reactions [35,36].

We have previously shown an induction of partial tolerance in CIA upon intravenous injection of lentiviral particles that code for the expression of the CII-peptide aa259-270 on MHCII in a fraction of host cells [37,38]. We hypothesize that a further increased expression of the tolerogen would induce complete CII-specific tolerance in CIA and allow detailed studies of immunological mechanisms. To this end we developed a mouse model using lentiviral based gene therapy in which the tolerogen is permanently expressed on MHCII Aq already before CIA is induced. In this model an almost complete and sustainable tolerance to CIA is established very early after immunization and shows the immunological complexity of tolerance and allows for further mechanistic studies in the field.

Competing Interests: The commercial funder AFA has not in any way influenced the present work. The authors have no relations with AFA other than an approved application for the present work and additional funding. The funding does not include employment, consultancy, patents, products in development or marketed products. The funding provided by AFA does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
Material and Methods

Lentiviral constructs

Generation of the CII expressing lentiviral vector (LNT-CII) has been described previously [37] (Fig 1A). Briefly, CII aa259–270 or CLIP amino acids were cloned into the class II–associated invariant chain peptide position of the invariant chain (II) to achieve efficient loading of and binding to MHCI. Next, the generated II-fragments were subcloned into the lentiviral vector pHR’SIN-cPPT-SFFV and named; LNT-CII and LNT-Ctrl. SFFV was used as a general promoter that ensures a high expression in all cell types.

Production of lentiviral particles

Vesicular stomatitis virus—G pseudotyped lentivirus was produced by transient transfection of 293FT cells with three plasmids; the self inactivating transfer vector plasmid LNT-CII or LNT-Ctrl, the multi-deleted packaging plasmid; pCMVRΔR8.74 and the VSV-G envelope; pMD.G2 and titrated as previously described [38].

Mice

Male DBA/1 mice 6–8 weeks old were obtained from Taconic (Europe A/S, Ry, Denmark) and housed in a pathogen-free barrier facility (12-hr light/12-hr dark cycle) and fed water and rodent chow. The chow was placed on the cage floor and the water bottle tip was reachable when the mice stood on four paws. All mice were monitored daily. All animal studies were approved by the local Animal Ethics Committee in Gothenburg, i.e. Göteborgs Djurförsöksnämnd, Kammarrätten i Göteborg, Box 1531, SE401 50 Göteborg, Sweden according to Swedish legislation. Ethical approvals and approval dates: 277–2011 (2011-09-11) and 233–2014 (2014-12-17). According to the ethical permission the mice were sacrificed by injection of an intraperitoneal injection of ketamine/medetomidin followed by opening of thorax and heart puncture. If the mice were affected by arthritis in the forepaws, scored higher than 5, they were euthanized as described above, and culled. In the present experiments, no mouse reached a score higher than 5 in the forepaws.

Lentiviral transduction and transplantation hematopoietic stem cells

Femurs from DBA/1 mice (Taconic) 7–10 weeks of age were obtained and the femurs were clean of muscles and tendons and subsequently hematopoietic stem cells were purified using Mouse Hematopoietic Progenitor Cell Enrichment Kit (Stemcell Technologies, Manchester, UK). Puriﬁed hematopoietic stem cells were cultivated at a concentration of 1x10⁶ cells/ml in a 12-well plate in StemSpan (Stemcell Technologies) overnight in the presence of 100ng/ml mSCF, 100ng/ml Flt-3L, 100ng/ml IL-11, 20ng/ml IL-3 (R&D Systems, Abingdon, UK) and lentiviral particles at multiplicity of infection 75 (i.e. 75 lentiviral particles/cell). The cells were resuspended in PBS the following day and subsequently injected intravenously (2.5x10⁵ cells/mouse) into syngenic lethally irradiated (8.5 Gray) recipient mice. The cells were allowed to repopulate the mice for a minimum of 10 weeks before start of the experiments (Fig 1B).

Collagen-induced arthritis

The mice were immunized with rat CII and complete Freund’s adjuvant (CFA, Sigma-Aldrich, Sweden) and boosted at day 21 or 28 (according to standard collagen-induced arthritis protocol [37]). Day of booster was changed from day 21 to 28 in the experiment shown in Fig 2D due to changes in the Swedish legislation. Arthritis severity and frequency were graded blindly and the arthritis (defined as visible erythema and/or joint swelling) was evaluated by inspection.
Antigen-Specific Tolerance in Arthritis

A

LNT-Ctrl 5'LTR cPPT SFFV li CLIP li WPRE Δ3LTR

LNT-CII 5'LTR cPPT SFFV li CII (258-270) li WPRE Δ3LTR

B

Transduction of cells with active LNT-CII or control LNT-Ctrl

Irradiation of recipient

Day 0

Immunization rat CII + CFA

Day 21 or 28

Booster rat CII + IFA

Evaluation of disease

10-12 weeks

C

Hydroxyl

Glycosyl

Naked

HdBr1 hybridoma

Hcq3 hybridoma

Hcq4 hybridoma

Peptide concentrations mg/ml

IL-2 pg/ml

D

Ctrl-HdBr1

Ctrl-Hcq3

Ctrl-Hcq4

CII-HdBr1

CII-Hcq3

CII-Hcq4

Bone marrow

Peritoneal macrophages

Spleen

E

LNT-Ctrl

LNT-CII

CD19^+ cells/Hcq4

CD19^+ cells/Hcq4
of finger/toe and ankle/wrist joints. A score was assigned for each limb: 0, neither swelling nor erythema; 1, mild swelling and/or erythema; 2, moderate swelling and erythema; and 3, marked swelling and erythema. The total score for each mouse was calculated by adding up the scores for each limb.

**Detection of CII-protein expression on MHCII**

To investigate the presentation of CII-peptide on MHCII molecules, T cell hybridomas specific for modified CII-peptides were used. Hcq3 hybridoma (recognizes glycosylated CII aa259-270), Hcq4 (recognizes naked CII aa259-270) and HdBr1 (recognizes hydroxylated CII aa259-270). To ensure proper specificity of the hybridoma, 5x10^4 cells from each hybridoma were co-cultured for 24h with 5x10^5 naïve unsorted splenocytes and stimulated with 100 ul of naked CII-peptide, hydroxylated CII-peptide or glycosylated CII-peptide. Analysis of IL-2 levels in supernatants was performed using sandwich ELISA (R&D Systems) and showed specific peptide responses for each hybridoma (Fig 1D). The specific T cells hybridoma were then used to investigate CII presentation on cells from peritoneal cavity, bone marrow and spleen, 12 weeks after transplantation. Peritoneal macrophages (PEM) and bone marrow cells from femur, tibia as well as splenocytes were harvested from unimmunized transplanted mice (n = 6/group) and seeded in 96-well plates in triplicates at a concentration of 5x10^5 cells/well and either of the T cell hybridomas injected into lethally irradiated recipient mice. CIA was induced according to standard protocol at least 10 weeks after HSC transplantation. (C) Naïve splenocytes were stimulated with naked, hydroxylated or glycosylated peptides and co-cultured with T cell hybridomas specific to each post-translational modification of the CII-peptide, i.e. Hcq4 recognizes the naked peptide, HdBr1 the hydroxylated and Hcq3 the glycosylated CII-peptide. The response was measured as IL-2 production by ELISA and performed three times. (D) IL-2 production in response to co-culture of the T cell hybridomas with bone marrow cells, peritoneal macrophages or spleen cells from HSC transplanted mice (n = 6/group) and performed twice. (E) Co-cultures of the T cell hybridomas with B cells (CD19^+) or non-B cells (CD19^-) from LNT-Ctrl and LNT-CII HSC transplanted mice (n = 3/group) and performed twice. Statistical analysis was performed by Student’s t-test, mean±SEM.
CII-specific antibodies in serum

Levels of CII-specific IgG in serum, taken at indicated time points after CII immunization, were determined by ELISA. Low binding plates (NUNC, Fisher Scientific, Gothenburg, Sweden) were coated with rat CII (1 μg/ml). Serum samples were diluted (1/6000, 1/18 000, 1/54...
and after incubation, CII-specific IgG was detected by using biotinylated rat anti-mouse IgG, IgG1, IgG2a or IgG2b at 0.5 μg/ml (Serotec, Oxford, UK). The assay was developed usingextravidin-horseradish peroxidase (HRP) and tetramethylbenzidine substrate. The reactions were stopped with H₂SO₄ and read in Spectra Max 340PC (Molecular Devices) at 450 nm and correction at 650 nm.

**Flow cytometry of B and T cells**

B and T cells were analyzed by flow cytometry (FACS) for expression of activation and differentiation markers. Briefly, single-cell suspensions were prepared from draining lymph nodes and spleen. Cells were resuspended in PBS with 10% FCS, counted (Nucleocounter) and seeded in 96-well plates. T cells were Fc blocked (clone 2.4G2 BD) before application of surface antibodies CD4 (V450 clone RM4-5, BD), CD4 (PB clone RM4-5, BD), CD25 (APC clone 3C7, BD) or CD25 (FITC, 3C7 BD) for 20 min in room temperature (RT). B cells were stained without prior Fc blocking using v450-labeled B220 (BD Biosciences) and APC-labeled CD93 for 20 min in RT. Intracellular staining was performed using FoxP3 / Transcription Factor Staining Buffer set (eBioscience) and FoxP3 (PE clone NRRF-30 eBioscience), FoxP3 (FITC, clone FJK-16s, eBioscience) or Helios (APC Alexa Fluor 647 clone 22F6 eBioscience) for 30 min in +8°C. Isotype controls were used as negative controls. Analysis was performed by FlowJo Software (Tree Star Inc., Ashland, OR, USA) and gates for surface staining were set according to fluorochrome minus one [39].

**Adoptive transfer**

Fourteen weeks after transplantation of lentivirally transduced HSCs, splenic T cells (defined as CD3⁺ cells), B cells (defined as both CD19⁺ and MHCII⁺) or the remaining MHC Class II⁺ pool (defined as CD19⁻ and MHCII⁻ cells, i.e. non-B APCs) were sorted by FACS Synergy. Briefly, single-cell suspensions were prepared in PBS with 10% FCS. APC Anti-Mouse CD3e (eBioscience), APC-Cy7 Rat Anti-Mouse CD19 (BD Pharmingen, US) and eFlour450 Anti-mouse MHC Class II (I-A/I-E) (eBioscience), respectively, were added to the cell suspensions. Following 30 min incubation at 4°C, cells were sorted by FACS. 7AA-D (BD Pharmingen, US) were added just prior sorting for exclusion of dead cells. Purity and viability of isolated cells was around 99 (S1 Fig). Freshly isolated cell populations (1x10⁶ T cells, 2x10⁶ B cells and 3x10⁵ APC cells/mouse) were adoptively transferred into naïve syngeneic recipient mice (Fig 3B–3D). Recipient mice were administered the cells 2 days prior to CII immunization and evaluated for development of arthritis as described above.

**Suppression and proliferation assays**

Cells from spleen were prepared as single cell suspensions. Antigen presenting cells were purified from spleen from LNT-Ctrl mice by negative selection using Mouse Dynabeads PanT kit (Life Technologies Ltd, Paisley, UK). CD4⁺ T cells were enriched using mouse CD4 negative selection kit (Life Technologies Ltd, Paisley, UK). Cell suspension was then stained for surface expression of CD4 (FITC, clone RM4-4, BD) and CD25 (APC clone 3C7, BD) as described earlier. T cells were sorted into a purified CD4⁺CD25⁻ T effector cell population and a CD4⁺CD25⁺ T population using FACS Sy3200 Sorter (Sony Biotechnology, Champaign, USA). Cells were primarily gated as lymphocytes based on size using FSC and SSC, and to ensure that cells were singlets, cells were gated as a single cell population using FSC-A and FSC-H. Cells were then gated as CD4⁺ and then CD25⁺ for sorting. Post sorting cells were analyzed for viability using 7-AAD (BD Biosciences) and purity. Sorted APCs (50000), T effector (18000) and Treg (according to ratio) cells were seeded in DMEM (supplemented with 10% FCS, 1% 2-mercaptoethanol, 1%
penicillin/streptomycin, here after called complete DMEM) with added anti-CD3 (azide free, BD) at a final concentration of 0.5 μg/ml in a 96-well plate. All co-cultures were incubated for 62h at 37°C, followed by addition of 1 μl H^3 thymidine (Perkin Elmer, Waltham, Massachusetts, USA) per well. After 12h cells were harvested and proliferation rate analyzed in Betacounter
Antigen-specific proliferation of whole spleen was performed at days 14 and 28 after CII immunization. Single cells were plated in triplicates at a concentration of $5 \times 10^5$ /well in a 96-well plate in DMEM (supplemented with 10% FCS, 1% 2-mercaptoethanol, 1% penicillin/streptomycin) and stimulated with rat CII 50 μg/ml for 72h. As a read out, IFN-γ was analyzed in the supernatant using a DuoSet kit (R&D).

**Cell ELISA**

Single cells from spleen cells and draining lymph node were plated in complete DMEM at a concentration of $5 \times 10^5$ cells/well in a 96-well plate and stimulated with 50 μg/ml CII and standard culture conditions. The supernatant was harvested after 72h, frozen in -20°C degrees and analyzed for TNF, IL-6, IL-10, TGF-β and IFN-γ using DuoSet ELISA (R&D).

**qPCR array analysis**

mRNA was prepared from lymph nodes from naïve mice (n = 3) and at from LNT-CII (n = 15) and LNT-Ctrl mice (n = 19) respectively at days 0, 3, 5, 14 and 28 after CII immunization using RNEasy Mini Kit and QIAcube (QIAGEN) with protocol RNeasy Mini Kit Cells and Tissue with DNase Digest according to the manufacturer’s instruction. RNA concentration was measured using a ND-1000 Spectrophotometer (NanoDrop). cDNA synthesis was made using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) including RNase inhibitor in a Veriti 96-Well Thermal Cycler (Applied Biosystems). cDNA was run in the 384-well microfluid card Taqman Array Mouse Immune Panel (Applied Biosystems/Life Technologies) detecting 90 + 6 genes using a Viia 7 Real-Time PCR System (Applied Biosystems/Life Technologies). β-actin (Actb) and GADPH (Gadph) were selected as housekeeping genes. Relative quantification (RQ) was calculated from the sample from a naïve DBA/1 mouse.

**Statistical analysis**

Statistical analyses were performed using GraphPad Prism (La Jolla, CA). Statistical differences between independent groups were calculated using the nonparametric Mann-Whitney U test for quantitative data and Fisher’s exact test for nominal data. Logistic regression was used to compare the development of arthritis between groups and linear regression was used to compare development of severity of arthritis between treatment groups. Two way ANOVA was used to compare cell proliferation in co-cultures of T cells in different ratios. Multivariate factor analysis (SIMCA-P+ software; Umetrics, Umea, Sweden) was used to examine the relation between LNT-Ctrl and LNT-CII mice (Y-variables) and the determined gene expression levels in the qPCR array analysis (X-variables). Orthogonal projection to latent structures DAs were implemented to examine whether tolerized mice compared with non-tolerized mice could be discriminated based on the various X-variables examined. The quality was assessed based on the parameters R2, that is, how well the variation of the variables is explained by the model, and Q2, that is, how well a variable can be predicted by the model. OPLS plots in the results are based on X-variables with variable influence on projection (VIP) values $>1.3$ VIP values can be used to discriminate between important and unimportant predictors for the model. In the OPLS analyses, the importance of each X-variable to Y is represented by column bars. Jackknifing was used to calculate SEs displayed as an error bar on each column (representing the 95% confidence interval). Univariate analyzes by student’s t-test were performed exclusively on the X-variables Socs1, IL-10, IFNg and IL-6 to avoid mass significance. P $< 0.05$ $^*$ was considered significant. P $< 0.005$ $^{**}$, P $< 0.001$ $^{***}$. **
Results
The CII-peptide is expressed in its naked form on MHCII in LNT-CII mice
To generate a tolerogenic lentiviral vector where the immunodominant CII-peptide, i.e. amino acids of CII (259–270), is presented on MHCII Aq by APCs, we cloned the CII-peptide aa259-270 DNA sequence into the CLIP position of the invariant chain (LNT-CII). The native CLIP peptide was kept as in the control vector (LNT-Ctrl) (Fig 1A) [37]. To express the CII-peptide on APCs, hematopoietic stem cells (HSC) were transduced with lentiviral particles and injected into lethally irradiated recipient mice (Fig 1B). The mice were allowed to reconstitute their hematopoietic cell populations for at least 10 weeks before CIA induction. After reconstitution we determined the expression of the CII-peptide/Aq on APCs using CII specific T cell hybridomas recognizing post-translational modified forms of the peptide [40]. All hybridomas were functional and responded as expected to their respective peptide (Fig 1C), and we found that it was predominantly the naked non-modified variant CII-peptide that was expressed in all assessed tissues: bone marrow, spleen and on peritoneal macrophages both before (Fig 1D) and day 28 after CII-immunization (S1 Fig). In spleens depleted of T cells both CD19 positive B cells as well as CD19 negative cells also expressed the naked non-modified variant of the CII-peptide (Fig 1E and S1 Fig).

Frequency and severity of arthritis are ameliorated in LNT-CII mice
The LNT-CII mice showed an almost complete resistance to develop arthritis (severity and frequency), by contrast to the LNT-Ctrl mice that developed a rapidly progressing arthritis (Fig 2A and 2B). These findings were confirmed by histopathology of the joints, which showed that only 6% of LNT-CII mice had mild signs of synovitis and erosivity, whereas >90% of LNT-Ctrl mice developed severe synovitis, and cartilage and bone destruction (Fig 2C and 2D). Thus, lentiviral gene therapy using LNT-CII that presents naked CII-tolerogen on APCs prevents development of CIA.

CII-specific IgG B cell responses are down-regulated in LNT-CII mice
It is known that the B cells and their production of CII-specific antibodies are crucial for the development of CIA [41,42]. The serum levels of CII-specific IgG antibodies, including the subclasses IgG1, IgG2a and IgG2b, were significantly lower in LNT-CII compared to LNT-Ctrl mice throughout the experiment (Fig 2E and 2F). This response was not due to a general effect on total immunoglobulin levels, which were unchanged (S2 Fig). The CII-specific IgM response was similar in both groups of mice both before and at days 29 and 47 after CII immunization (S2 Fig). These findings indicate that only the T cell dependent production of antigen-specific IgG is affected by the induced tolerance.

B cells and non-B cells mediate tolerance to arthritis in LNT-CII mice
There are three main cell types that can contribute to immunological tolerance: Treg, APCs and B cells. To investigate the role of each of these cell population in our tolerance model, we isolated splenic T cells, B cells and the remaining non-B cell APC pool from mice after gene therapy (S1 Fig). The isolated cell populations were transferred into naïve syngeneic recipients two days before CIA was induced (Fig 3A). There were no differences between the two groups of mice in the composition and proportion of cells before transfer with respect to leukocytes, lymphocytes, CD4+ T cells, CD4+ Foxp3+ Tregs, MHCII+CD19+ B cells or MHCII+CD19- non-B cell APCs (S3 Fig and Table 1). The macroscopically observed development of arthritis was significantly ameliorated after transfer of splenic B cells (Fig 3B), non-B APCs (Fig 3C) or
T cell from LNT-CII mice (Fig 3D). However, histopathological examination showed that transfer of B cells, but also of T cells from LNT-CII mice reduced the degree of synovitis and cartilage and bone destruction (Fig 3E). The histopathological differences in the joints between the groups after transfer of non-B cell APCs were not as pronounced as for the other cell types transferred, though this could be due to the lower amount of cells transferred (Fig 3E). At the termination of the T cells transfer experiment we analyzed the serum levels of CII-specific IgG in total and of all subclasses and found no statistical differences between the respective groups (S4 Fig). Thus, transfer of T cells, B cells and non-B cell APCs from LNT-CII mice suppressed the macroscopically observed severity of CIA, which indicates that tolerance can be induced and maintained by multiple cell types.

The suppressive Treg function is enhanced in LNT-CII mice

Induction of tolerance by T cells could potentially be attributed to Tregs [43–45]. We assessed the proportion of Tregs (CD4⁺Foxp3⁺ cells) at days 0, 3, 5, 28 and 49 after CIA induction. The proportion of Tregs in the spleen and lymph nodes was increased at day 3 in LNT-CII compared to LNT-Ctrl (Table 1). However, at day 5 the proportions of Tregs were reduced in LNT-CII compared to those in LNT-Ctrl mice (Table 1, gating strategy S5 Fig). This suggests that events crucial for tolerance take place very early after immunization with CII. To investigate whether the suppressive function of Tregs was enhanced in LNT-CII mice, we purified T effector cells (CD4⁺CD25⁺) from LNT-Ctrl and Tregs (CD4⁺CD25⁺) from immunized LNT-CII and LNT-Ctrl mice (S6 Fig). Stimulation with anti-CD3 antibodies showed that Tregs from LNT-CII but not LNT-Ctrl mice significantly reduced the proliferative response of the T effector cells (Fig 4A). Unexpectedly, unsorted spleen cultures (characterized in S7 Fig and S8 Fig) from LNT-CII mice stimulated with CII showed a tendency to increased IFN-γ production at day 14 compared to LNT-Ctrl mice (Fig 4B). Taken together, this suggests that Tregs from LNT-CII mice are an important mediator of the tolerogenic phenotype.

LNT-CII has limited effect on cytokine levels

Pathogenesis of CIA is characterized by a Th1 and Th17 response that is counter-acted by regulatory cytokines such as IL-10, IL-4 and TGF-β [46,47]. To analyze the cytokine pattern during the course of CIA mRNA levels of TNF-α, IFN-γ, IL-4 and IL-17A in draining lymph nodes were determined. In addition, protein levels of TNF-α, IFN-γ, IL-6, IL-10 and TGF-β in serum as well as draining lymph node cultures at day 49 after immunization were assessed. Despite the significant differences in arthritis outcome, there were no differences between the groups in the levels of any of these mRNA or proteins except IFN-γ, which was decreased in

Table 1. Proportion of CD4⁺Foxp3⁺ Tregs of CD4⁺ cells in spleen and draining lymph nodes before and after immunization.

| Tissue       | Mice      | Day | 0      | 3      | 5      | 28     | 49     |
|--------------|-----------|-----|--------|--------|--------|--------|--------|
| Spleen       | LNT-Ctrl  |     | 26.1 ± 0.6 | 22.6 ± 0.6 | 25.9 ± 0.2 | 28.0 ± 1.2 | 21.5 ± 1.6 |
| Spleen       | LNT-CII   |     | 25.5 ± 1.8 | 26.1 ± 0.2** | 24.2 ± 0.3* | 24.1 ± 1.0* | 21.1 ± 1.2 |
| Lymph nodes  | LNT-Ctrl  |     | 11.8 ± 0.9  | 12.0 ± 0.8  | 12.6 ± 0.7  | ND      | ND     |
| Lymph nodes  | LNT-CII   |     | 12.37 ± 0.4 | 14.9 ± 0.6* | 11.7 ± 0.9  | ND      | ND     |

*p<0.05 and **p<0.01 LNT-Ctrl vs LNT-CII. Data presented as mean ± SEM. At day 0, 3, 5 and 28 n = 3, at day 49 n = 5–6 per group, ND; not done.

doi:10.1371/journal.pone.0154630.t001
lymph node cultures from LNT-CII (mean ± SEM pg/ml; 22.1 ± 3.86) compared to LNT-Ctrl (50.08 ± 8.8, p = 0.03).

**Early increase in Socs1 expression levels is associated with tolerance**

As it proved difficult to explain the tolerant phenotype by one single factor at a certain time point, an immune card array that detects mRNA levels of 90 different genes was employed on draining lymph nodes 0, 3, 5, 7, 14 and 28 days after CII immunization. Multivariate
discriminant analysis, OPLS-DA, indicates that the gene expression profile is different in LNT-CII vs LNT-Ctrl mice at all time points (Fig 5A and S9 Fig). The variables that displayed the strongest association (positive or negative) with either group of mice are identified in the column plots (Fig 5B and S9 Fig). Variables with a positive bar are positively associated with LNT-CII mice whereas variables with bars in the opposite direction are inversely related to the LNT-CII mice.

At day 3 after CII immunization the OPLS-DA analysis showed that the mRNA expression of Socs1 along with Il10 associated strongly with LNT-CII mice, while Ifng associated with LNT-Ctrl mice (Fig 5B). The individual values of mRNA expression of Socs1, Il10, Ifng and Il6 during the course of arthritis are plotted in Fig 5C–5F. Day 3 after CII immunization is also the only time point where the proportion of Tregs was increased in tolerated LNT-CII mice (Table 1). Thus, the early increase in Socs1 mRNA coincides with the increased frequency of Tregs and resistance to arthritis development.

**Discussion**

In this study we demonstrate that transfer of hematopoietic stem cells expressing the CII-peptide on MHCIi Aq (LNT-CII) to lethally irradiated mice induces an almost complete antigen-specific tolerance CIA. We show that only 5% of the CII-tolerized mice developed a mild synovitis while more than 95% of control mice developed a severe synovitis as well as severe cartilage and bone destruction. We found that early events including up-regulation of SOCS1 and an increased proportion of Tregs associated with resistance to arthritis development. We demonstrate that the tolerance to CIA caused by excessive presentation of the CII-tolerogen on APCs is a process with multiple immunological effector mechanisms, as transfer of both T cells, B cells and to some extent also MHCIi+ cells from CII-tolerized mice to naïve recipients ameliorate the course and severity of arthritis. Further, the OPLS-DA analyses of mRNA expression from peripheral lymph nodes clearly shows that tolerance mechanisms differ substantially between CII-tolerized and control mice but also between different time points throughout the course of CIA.

It is well known that Tregs are generated both in the thymus and in peripheral tissues [48] and that functional Tregs cells are pivotal to maintain immunological homeostasis [49]. We demonstrate that early after CII immunization (day 3) there is an increased proportion of Tregs and up-regulation of the mRNA expression of SOCS1 and IL-10 in tolerant LNT-CII mice. At the same time, LNT-CII mice also down-regulate mRNA expression of IFN-γ and to some extent IL-6. IL-10 is a known inducer of SOCS1 [50], and we have previously shown that the CIA is alleviated in the presence of an increased IL-10 production, which coincided with an increased SOCS1 expression in draining lymph nodes and reduced serum levels of IL-6 [34]. SOCS1 prevents JAK/STAT signaling, and plays an important role in Tregs by maintaining Foxp3 expression and by suppressing IFN-γ and IL-17 production [51]. Thus, we hypothesize that tolerance is established very early after CII immunization, and that it involves both generation of Tregs as well as SOCS1 that shuts down the CII-specific effector response. This hypothesis is further supported by clinical studies showing that tolerance induction is more successful if the host’s immune system has a tolerogenic phenotype [52].

We also found that suppressive capacity of Tregs from tolerant LNT-CII mice was preserved after general stimulation with anti-CD3, while the suppressive capacity of LNT-Ctrl Tregs was decreased. This may be due to the inflammatory status in these animals, since it has been shown that in RA the Tregs are under the influence of the cytokine milieu and that this has a negative effect on their suppressive function, e.g. anti-TNF treatment has been shown to improve Treg function [53]. Another explanation could be that the proportion of antigen
Fig 5. qPCR array and SOCS1 association with LNT-Ctrl vs LNT-CII at day 3 after CII immunization. (A) OPLS-DA scatter dot plot showing the separation of gene expression in tolerized or non-tolerized mice and (B) OPLS-DA column loading plot that depicts the association between LNT-CII and LNT-Ctrl mice with the expression of different genes. X-variables represented with a positive bar are positively associated with LNT-CII mice, whereas variables in the opposite direction are inversely related to this group of mice. The larger the bar and smaller the error bar, the stronger and more certain is the association.
(CII)-specific Tregs and T effector cells in LNT-CII is altered compared to LNT-Ctrl mice. It is likely that both an increased induction of antigen (CII)-specific Tregs as well as fewer antigen (CII)-specific T effector cells operate in LNT-CII mice as the CII-peptide is presented on both B cells and non-B cell APCs.

Earlier studies have highlighted that post-translational glycosylation of the CII-epitope is important for arthritis development in the CIA model [54]. Further, CII-autoreactive T cells that recognize the glycosylated CII-epitope have been found in blood and synovial fluids from patients with RA, and there is a significant correlation between disease activity and T cell response to the glycosylated CII-epitope [55]. It has also previously been shown that overexpression of the glycosylated CII-epitope is superior to the naked epitope in tolerance induction to CIA [14]. We show that it is the naked rather than the glycosylated CII-peptide that is presented, which can be due to difficulties for the APC to glycosylate the CII-peptide in our experimental system. Nevertheless, overexpression of the naked CII-peptide induces tolerance to CIA [37,38], though it is possible that the tolerogenic effect might have been even better if the glycosylated CII-peptide was expressed. The discrepancies between the findings regarding the tolerogenic effects of glycosylated and naked CII-peptide may be explained by yet unpublished work showing that it is the non-modified naked CII peptide that is presented in thymus (personal communication, J Bäckström, KI). This implies that central tolerance mechanisms are important and it would in future studies be very interesting to perform thymectomy prior to irradiation, repopulation and induction of arthritis to further decipher the puzzle of tolerance. Also supporting a role for central tolerance in autoimmune arthritis is the fact that aberrant ZAP-70, a key signal transduction molecule in T cells during thymic selection changes the thresholds of T cells to thymic selection, leading to the positive selection of otherwise negatively selected autoimmune T cells and to subsequent development of chronic autoimmune arthritis in mice [56].

Intravenous administration of lentiviral particles encoding LNT-CII/LNT-Ctrl either before or after CII immunization induces partial tolerance to CIA [37,38], while transplantation of lentivirally transduced HSCs induces an almost complete tolerance. The main reasons in efficacy between the two delivery systems are most likely the amount of time between transfer of lentiviral particles and CII immunization, and the impact as well as the amount of the CII-peptide expression in the mouse. After transfer of transduced HSCs, the immune system was allowed to repopulated for > 10 weeks, while the lentiviral particles were injected either 30 days before or, at different time points after CII-immunization. Transfer of transduced HSCs to a lethally irradiated mouse leads to differences in function, but not in proportions, of immune cells already before CII-immunization (Fig 5 and S9 Fig). It is also well known that presentation of a high amount of antigen without co-simulation leads to tolerance. The expression of the CII-peptide was detectable with the T cell hybridomas after transfer of lentiviral transduced HSCs (Fig 1D), but not after intravenous injection that indicates that there is a lower presentation of the peptide.

B cells are potent professional APCs that have been previously implicated in tolerance induction and disease development [27,57,58]. The B cells contribute to CIA both by presenting antigens and by producing cytokines and CII-specific antibodies [59]. In the tolerogenic LNT-CII mice, there is a profound reduction of the B cell response, and as this require T cell activation, these data support an increased suppression by Tregs and a reduction in antigen-
specific T effector cells. Further, self-antigen expression by B cells has been shown to be very efficient in inducing Tregs in the periphery, whereas self-antigen expression by DC led mainly to deletion and anergy of antigen-specific T effector cells [24].

From day 5 and onwards after CII immunization we could not detect a general increase in the proportion of Tregs in the tolerant LNT-CII mice, but rather the opposite as the proportion of Tregs increased in the arthritic LNT-Ctrl mice. This could be explained by the absence of an ongoing immune response in LNT-CII mice, while the arthritic LNT-Ctrl mice need to mobilize their Tregs to limit the ongoing inflammation, as it is well known that Tregs increase during inflammation [60].

The kinetics of IFN-γ in the LNT-CII mice is interesting. The levels are decreased compared to LNT-Ctrl mice at day 3, increased at day 14, similar at day 28 and decreased at day 49 after CII immunization. This most likely mirrors that there are different effector mechanisms governing the tolerogenic state at different time points. IFN-γ has both regulatory and immune stimulating properties. It can inhibit osteoclastogenesis and formation Th17 cells, as well as facilitate the induction and increase the suppressive capacity of Tregs, and in addition up regulate MHCII as well CD80/86 expression (reviewed in [61]). IFN-γ is also of importance for B cell responses and IFN-γ production by T follicular helper cells is necessary for germinal centre formation and the production of high affinity antibodies [62].

Regulatory B cells can also influence the inflammatory response [63]. Regulatory B cells are defined either by IL-10 production or by surface markers including for B220/CD23/CD24/IgM/CD1d [58], however our data (not shown) do not support an increased B regulatory cell compartment. Thus, the reduced B cell response in tolerant LNT-CII mice is most likely secondary to lack of a CII-specific T cell response.

To summarize, we have shown that a sustainable tolerance against CIA can be established by endogenous expression of naked unglycosylated CII-peptide on MCHII. Tolerance is established very early during the course of arthritis and can be mediated by both B and non-B cells as antigen presenting cells. We suggest that the model we have established using lentiviral constructs can be used to elucidate the detailed functions of not only tolerogenic states in CIA, but also in other experimental autoimmune models.

Supporting Information

S1 Fig. Gating strategy, purity and viability of cells used in CII-peptide presentation assay and adoptive transfer and CII-peptide expression. (A) Detection of the CII-peptide in splenocytes by T cell specific hybridomas at day 28 after transfer of lentivirally transduced HSCs. (B) Verification of the functionality of the hybridomas. (C) Purity of non-B cells APCs and B cells used for the experiment in Fig 1E. (D) FACS sorting of B cells and T cells was initiated through gating for BSC area vs FALS area followed by gating for 7-AAD. T cell sorting was performed by gating for CD3+ or CD19- cells. Sorting of B cells was performed gating for MHCII positive CD19+ cells and sorting non B cell APCs gating for MHCII+ CD19- cells. (E) Flow cytometry using BSC area (y-axis) vs 7-AAD (x-axis) to estimate cell viability and purity of the sorted cells using MHCII (y-axis) vs CD19 (x-axis) for B cells and CD3 (y-axis) vs CD19 (x-axis) for T cells.

(SPS)

S2 Fig. Serum levels of general IgG and CII-specific IgM. (A) Serum levels of general IgG at day 49 after CII immunization, n = 7+6 mice. (B) Serum levels of CII-specific IgM antibodies at day 0, 27 and 49 after CII immunization, n = 6+6 mice. Goat anti-mouse polyclonal IgG antibodies (Jackson Immunology Research, Suffolk, England) was used as coating, and 2% BSA (Sigma-Aldrich) for blocking. Serum samples were serially diluted from 1/ 7500 to 1/202 500)
The total IgG levels in serum were detected by a biotinylated goat anti-mouse IgG (Southern Biotechnology, Alabama, USA) or biotinylated (Fab)_2 goat antimouse IgM (Jackson ImmunoResearch Laboratories). The assays were developed using extravidin-horseradish peroxidase (HRP) and tetramethylbenzidine substrate. The reactions were stopped with H_2SO_4 and read in Spectra Max 340PC (Molecular Devices) at 450 nm and correction at 650 nm. Data were expressed as optical density (OD).

**S3 Fig. Cell population before and after CII immunization.** (A) The absolute number of leukocytes and lymphocytes in blood before CII immunization, n = 6+7 mice were counted in a Sysmex Cell counter. The distribution of (B) CD4^+^, CD19^+^ MHC II^+^ and CD19 MHC II^+^ cells in blood before CII immunization, (C) lymph nodes and (D) bone marrow. (E) Intracellular expression of Foxp3 and CTLA in CD4^+^CD25^+^ T cells from lymph nodes before CII immunization, n = 3+4 mice. (F) Expression level (MFI) of CD62L on CD4^+^ cells in blood (G) MFI of MHCII on CD19^+^ and (H) CD19^+^ cells in blood before and during the course of arthritis, each mouse is shown as individual dots. The cells were stained for flow cytometry as previously described.

**S4 Fig. Serum levels of CII-specific IgG after adoptive transfer of T cells, day 39 after CII immunization.** The different subclasses of IgG as well of CII-specific total IgG are indicated, n = 6+6 mice.

**S5 Fig. Gating strategies and phenotype of Tregs.**

**S6 Fig. Phenotypes of cells in the T cell suppression experiments.** (A-B) Gating strategy and purity of CD4^+^CD25^+^ T cells in the T cell suppression assay (Fig 4A). (C) Purity of T cell depleted antigen presenting splenocytes used in the T cell suppression assay (Fig 4A).

**S7 Fig. Phenotype of B cells and non-B cell APC at day 14 after CII-immunization.** The following antibodies for flow cytometry CD21-Fitc, CD23-PE-Cy7, CD93-APC, CD19-V450, IgD-bio/PerCP and MHCII-PE were used.

**S8 Fig. Phenotype of CD4 positive T cells in spleen at days 14 and 28 after CII-immunization.**

**S9 Fig. qPCR array and SOCS1 association with LNT-Ctrl vs LNT-CII at days 0, 5, 14 and 28 after CII immunization.** (A, C, E, G) OPLS-DA scatter dot plot showing the separation of gene expression in tolerized or non-tolerized mice. (B, D, F, H) show the OPLS-DA column loading plot that depicts the association between LNT-CII and LNT-Ctrl mice with the expression of different genes. X-variables represented with a positive bar are positively associated with LNT-CII mice, whereas variables in the opposite direction are inversely related to this group of mice. The OPLS-DA column plots are based on variables with VIP values ≥1.3. R2Y indicates how well the variation of Y is explained, whereas Q2 indicates how well Y can be predicted.
Acknowledgments

This study was supported by grants from the Swedish Science Research Council (Medicinska Forskningsrådet, Gjertsson, Mårtensson, Holmdahl), Goteborg’s Läkaresällskap (Gjertsson), Svenska Läkaresällskapet (Gjertsson), King Gustav V’s 80 Year Fundation (Gjertsson, Mårtensson). AFA Insurances* (*AFA Insurance is an organization owned by Sweden’s labour market parties (Gjertsson, Mårtensson). IngaBritt och Arne Lundbergs Forskningsstiftelse (Mårtensson). Primer and probe sequences, and plasmid standards for real-time PCR quantification of the titin gene were kindly provided by Dr Anne Galy, Genethon, France. Plasmids pCMVΔR8.74 and pMD.G2 produced Plasmid Factory, GmbH&Co. KG, Bielefeld, Germany.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

Author Contributions

Conceived and designed the experiments: ST TE RH KG IG. Performed the experiments: ST TE PJ KW AS ILM LH IG. Analyzed the data: ST TE OT KW RH AS ILM IG. Contributed reagents/materials/analysis tools: JK RH. Wrote the paper: ST TE ILM AS KW RH IG.

References

1. Boyman O, Comte D, Spertini F Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 2014 10: 612. doi: 10.1038/nrrheum.2014.123 PMID: 25112605
2. Cooles FA, Isaacs JD Treating to re-establish tolerance in inflammatory arthritis—lessons from other diseases. Best Pract Res Clin Rheumatol 2010 24: 497. doi: 10.1016/j.berh.2010.01.007 PMID: 20732648
3. Myers LK, Brand DD, Ye XJ, Cremer MA, Rosloniec EF, Bodo M, et al. Characterization of recombinant type II collagen: arthritogenicity and tolerogenicity in DBA/1 mice. Immunology 1998 95: 631. PMID: 9893056
4. Michaelsson E, Andersson M, Engstrom A, Holmdahl R Identification of an immunodominant type-II collagen peptide recognized by T cells in H-2q mice: self tolerance at the level of determinant selection. Eur J Immunol 1992 22: 1819. PMID: 1378019
5. Brunsberg U, Gustafsson K, Jansson L, Michaelsson E, Ahrlund-Richter L, Pettersson S, et al. Expression of a transgenic class II Ab gene confers susceptibility to collagen-induced arthritis. Eur J Immunol 1994 24: 1698. PMID: 8026530
6. Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke GJ Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A 1986 83: 7443. PMID: 3463976
7. Khare SD, Krc CJ, Griffiths MM, Luthra HS, David CS Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. J Immunol 1995 155: 3653. PMID: 7561065
8. Zhu P, Li XY, Wang HK, Jia JF, Zheng ZH, Ding J, et al. Oral administration of type-II collagen peptide 250–270 suppresses specific cellular and humoral immune response in collagen-induced arthritis. Clin Immunol 2006.
9. van Vollenhoven RF, Nagler-Anderson C, Soriano A, Siskind GW, Thorbecke GJ Tolerance induction by a poorly arthritogenic collagen II can prevent collagen-induced arthritis. Cell Immunol 1988 115: 146. PMID: 3401929
10. Ito HO, So T, Ueda T, Imoto T, Koga T Prevention of collagen-induced arthritis (CIA) by treatment with polyethylene glycol-conjugated type II collagen; distinct tolerogenic property of the conjugated collagen from the native one. Clin Exp Immunol 1997 107: 213. PMID: 9158088
11. Chu CQ, Londei M Differential activities of immunogenic collagen type II peptides in the induction of nasal tolerance to collagen-induced arthritis. J Autoimmun 1999 12: 35. PMID: 10028020
12. Hasselberg A, Schon K, Tarkowski A, Lycke N Role of CTA1RTK-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis. Arthritis Rheum 2009 60: 1672. doi: 10.1002/art.24556 PMID: 19479868
13. Michaelsson E, Malmstrom V, Reis S, Engstrom A, Burkhardt H, Holmdahl R T cell recognition of carbohydrates on type II collagen. J Exp Med 1994 180: 745. PMID: 8046350
14. Dzhambazov B, Nandakumar KS, Kihlberg J, Fugger L, Holmdahl R, Vestberg M. Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J Immunol 2006 176: 1525. PMID:16424181

15. Myers LK, Sakurai Y, Tang B, He X, Rosloniec EF, Stuart JM, et al. Peptide-induced suppression of collagen-induced arthritis in HLA-DR1 transgenic mice. Arthritis Rheum 2002 46: 3369. PMID:12483744

16. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000 6: 1176. PMID:11017151

17. Kervran A, Dubrasquet M, Blache P, Martinez J, Bataille D. Metabolic clearance rates of oxyntomodulin and glucagon in the rat: contribution of the kidney. Regul Pept 1990 31: 41. PMID:2270317

18. Min SY, Hwang SY, Park KS, Lee JS, Lee KE, Kim KW, et al. Induction of IL-10-producing CD4+CD25+ T cells in animal model of collagen-induced arthritis by oral administration of type II collagen. Arthritis Res Ther 2004 6: R213. PMID:15142267

19. Carranza F, Falcon CR, Nunez N, Knubel C, Correa SG, Bianco I, et al. Helminth antigens enable CpG-activated dendritic cells to inhibit the symptoms of collagen-induced arthritis through Foxp3+ regulatory T cells. PLoS One 2012 7: e40356. doi: 10.1371/journal.pone.0040356 PMID:22848374

20. Jaen O, Rulle S, Bessis N, Zago A, Boissier MC, Falgarone G. Dendritic cells modulated by innate immunity improve collagen-induced arthritis and induce regulatory T cells in vivo. Immunology 2009 126: 35. doi: 10.1111/j.1365-2657.2008.02875.x PMID:18754812

21. Park MJ, Park KS, Park HS, Cho ML, Hwang SY, Min SY, et al. A distinct tolerogenic subset of splenic IDO(+)/CD11b(+) dendritic cells from orally tolerized mice is responsible for induction of systemic immune tolerance and suppression of collagen-induced arthritis. Cell Immunol 2012 278: 45. doi: 10.1016/j.cellimm.2012.06.009 PMID:23121975

22. Ning B, Wei J, Zhang A, Gong W, Fu J, Jia T, et al. Antigen-Specific Tolerogenic Dendritic Cells Ameliorate the Severity of Murine Collagen-Induced Arthritis. PLoS One 2015 10: e0131152. doi:10.1371/journal.pone.0131152 PMID:26107250

23. Yanaba K, Hamaguchi Y, Venturi GM, Steeber DA, St Clair EW, Tedder TF. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol 2007 179: 1369. PMID:17617630

24. Morlacchi S, Soldani C, Viola A, Sarukhan A. Self-antigen presentation by mouse B cells results in regulatory T-cell induction rather than anergy or clonal deletion. Blood 2011 118: 984. doi: 10.1182/blood-2011-02-336115 PMID:21652680

25. Mauri C, Chu CQ, Woodrow D, Mori L, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003 197: 489. PMID:12591906

26. Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR, et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007 178: 7868. PMID:17548625

27. Carter NA, Rosser EC, Mauri C. Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory 1 cells and reduction of collagen-induced arthritis. Arthritis Res Ther 2012 14: R32. doi: 10.1186/ar3736 PMID:22315945

28. Ding Y, Chen D, Tarcsafalvi A, Su R, Qin L, Bromberg JS. Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses. Journal of immunology 2003 170: 1383.

29. Tamura Y, Kashiwagi I, Takahashi R, Yasukawa H, Yoshimura A. Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol 2011 31: 980. doi:10.1161/ATVBAHA.110.207464 PMID:21508344

30. Liang Y, Xu WD, Peng H, Pan HF, Ye DQ. SOCS signaling in autoimmune diseases: molecular mechanisms and therapeutic implications. Eur J Immunol 2014 44: 1265. doi:10.1002/eji.201344369 PMID:24595859

31. Sharabi A, Stoeger ZM, Mahlab K, Lapter S, Zinger H, Mozes E. A tolerogenic peptide that induces suppressor of cytokine signaling (SOCS)-1 restores the aberrant control of IFN-gamma signaling in lupus-affected (NZB x NZW)F1 mice. Clin Immunol 2009 133: 61. doi:10.1016/j.clim.2009.06.010 PMID:19631585

32. Sharabi A, Stoeger ZM, Mahlab K, Lapter S, Zinger H, Mozes E. A tolerogenic peptide that induces suppressor of cytokine signaling (SOCS)-1 restores the aberrant control of IFN-gamma signaling in lupus-affected (NZB x NZW)F1 mice. Clin Immunol 2009 133: 61. doi:10.1016/j.clim.2009.06.010 PMID:19631585

33. Veenbergen S, Bennink MB, Affandi AJ, Bessis N, Biton J, Amitz OJ, et al. A pivotal role for antigen-presenting cells overexpressing SOCS3 in controlling invariant NKT cell responses during collagen-
induced arthritis. Annals of the rheumatic diseases 2011 70: 2167. doi: 10.1136/ard.2011.154815 PMID: 21873688

34. Henningsson L, Eneljung T, Jirholt P, Tengvall S, Lidberg U, van den Bergh WB, et al. Disease-dependent local IL-10 production ameliorates collagen induced arthritis in mice. PLoS one 2012 7: e49731. doi: 10.1371/journal.pone.0049731 PMID: 23166758

35. Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 2010 142: 914. doi: 10.1016/j.cell.2010.08.012 PMID: 20850013

36. Larkin J 3rd, Ahmed CM, Wilson TD, Johnson HM Regulation of interferon gamma signaling by suppressors of cytokine signaling and regulatory T cells. Front Immunol 2013 4: 469. doi: 10.3389/fimmu.2013.00469 PMID: 24391443

37. Gjertsson I, Laurie KL, Thrasher AJ, Holmdahl R, et al. Tolerance Induction Using Lentiviral Gene Delivery Delays Onset and Severity of Collagen II Arthritis. Mol Ther 2009 Apr; 17(4): 632. doi: 10.1038/mt.2009.299 PMID: 19174762

38. Eneljung T, Tengvall S, Jirholt P, Henningsson L, Holmdahl R, Gustafsson K, et al. Antigen-specific gene therapy after immunisation reduces the severity of collagen-induced arthritis. Clin Dev Immunol 2013 2013: 345092. doi:10.1155/2013/345092 PMID: 24371448

39. Perfetto SP, Chattopadhyay PK, Roederer M Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol 2004 4: 648. PMID:15286731

40. Corthay A, Backlund J, Broddefalk J, Michaelsson E, Goldschmidt TJ, Kihlberg J, et al. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. Eur J Immunol 1998 28: 2580. PMID:9710235

41. Jansson L, Holmdahl R Genes on the X chromosome affect development of collagen-induced arthritis in mice. Clin Exp Immunol 1993 94: 459. PMID: 8252807

42. Nandakumar KS, Bajtner E, Hill L, Bohm B, Rowley MJ, Bakundu J, et al. Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. Arthritis Rheum 2008 58: 184. doi:10.1002/art.23049 PMID: 18163493

43. Morgan ME, Flierman R, van Duivenvoorde LM, Witteveen HJ, van Ewijk W, van Laar JM, et al. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum 2005 52: 2212. PMID: 15986351

44. Wright GP, Notley CA, Xue SA, Bendle GM, Holler A, Schumacher TN, et al. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci U S A 2009 106: 19078. doi:10.1073/pnas.0903961106 PMID: 19884493

45. Kelchtermans H, Geboes L, Mitera T, Huskens D, Leclercq G, Matthys P Activated CD4+CD25+ regulatory T cells inhibit osteoclastogenesis and collagen-induced arthritis. Ann Rheum Dis 2009 68: 744. doi: 10.1136/ard.2007.086066 PMID: 18480308

46. Brand DD, Kang AH, Rosloniec EF Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol 2003 25: 3. PMID: 12904888

47. Peck A, Mellins ED Breaking old paradigms: Th17 cells in autoimmune arthritis. Clin Immunol 2009 132: 295. doi: 10.1016/j.clim.2009.03.522 PMID: 19403336

48. Sakaguchi S Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004 22: 531. PMID: 15032588

49. Sakaguchi S, Yamaguchi T, Nomura T, Ono M Regulatory T cells and immune tolerance. Cell 2008 133: 775. doi:10.1016/j.cell.2008.05.009 PMID: 18510923

50. Fujimoto M, Naka T SOCS1, a Negative Regulator of Cytokine Signals and TLR Responses, in Human Liver Diseases. Gastroenterol Res Pract 2010 2010.

51. Takahashi R, Nishimoto S, Muto G, Sekiya T, Tamiya T, Kimura A, et al. SOCS1 is essential for regulatory T cell functions by preventing loss of Foxp3 expression as well as IFN-(gamma) and IL-17A production. J Exp Med 2011 208: 2055. doi:10.1084/jem.20110428 PMID: 21893603

52. Huurman VA, Velthuis JH, Hilbrands R, Tree TI, Gillard P, van der Meer-Prins PM, et al. Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am J Transplant 2009 9: 382. doi:10.1111/j.1600-6143.2008.02479.x PMID: 19067657

53. Nadkarni S, Mauri C, Ehrenstein MR Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007 204: 33. PMID: 1720049

54. Dzhambashov B, Holmdahl M, Yamada H, Lu S, Vestergaard M, Holm B, et al. The major T cell epitope on type II collagen is glycosylated in normal cartilage but modified by arthritis in both rats and humans. Eur J Immunol 2005 35: 357. PMID: 15682451
55. Snir O, Widhe M, Hermansson M, von Spee C, Lindberg J, Hensen S, et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 62: 44. doi: 10.1002/art.25036 PMID: 20039432

56. Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, Yamazaki S, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003 426: 454. PMID: 14647385

57. Dunussi-Joannopoulos K, Hancock GE, Kunz A, Hegen M, Zhou XX, Sheppard BJ, et al. B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model. Blood 2005 106: 2235. PMID: 15947095

58. Mauri C, Menon M The expanding family of regulatory B cells. Int Immunol 2015.

59. Behrens M, Smart M, Luckey D, Luthra H, Taneja V To B or not to B: role of B cells in pathogenesis of arthritis in HLA transgenic mice. J Autoimmun 2011 37: 95. doi: 10.1016/j.jaut.2011.05.002 PMID: 21665435

60. Josefowicz SZ, Lu LF, Rudensky AY Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012 30: 531. doi: 10.1146/annurev.immunol.25.022106.141623 PMID: 22224781

61. Billiau A, Matthys P Collagen-induced arthritis and related animal models: how much of their pathogenesis is auto-immune, how much is auto-inflammatory? Cytokine Growth Factor Rev 2011 22: 339. doi: 10.1016/j.cytogfr.2011.11.003 PMID: 22119010

62. Lee SK, Silva DG, Martin JL, Pratama A, Hu X, Chang PP, et al. Interferon-gamma excess leads to pathogenic accumulation of follicular helper T cells and germinal centers. Immunity 2012 37: 880. doi: 10.1016/j.immuni.2012.10.010 PMID: 23159227

63. Bouaziz JD, Le Buanec H, Saussine A, Bensussan A, Bagot M IL-10 producing regulatory B cells in mice and humans: state of the art. Curr Mol Med 2012 12: 519. PMID: 22292445